Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Rhea-AI Summary

Opus Genetics (Nasdaq:IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs), has announced its participation in four major scientific conferences in September 2025.

Key presentations include a discussion on gene and cell therapies at the Ophthalmology Futures Forum in Paris, one-year results from a Phase I/II study of OPGx-LCA5 at the International Symposium on Retinal Degeneration in Prague, and industry insights at the LSX World Congress in Boston. Dr. Sally Tucker and Dr. Ash Jayagopal will be among the key presenters sharing updates on the company's progress in retinal disease treatments.

News Market Reaction

-0.41%

2 alerts

-0.41% News Effect

-$296K Valuation Impact

$72M Market Cap

1.1x Rel. Volume

On the day this news was published, IRD declined 0.41%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $296K from the company's valuation, bringing the market cap to $72M at that time.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that it will present on its IRD gene therapy programs at the following scientific conferences in September 2025.

Presentation Details:

Ophthalmology Futures Forum (Retina Forum)

Title: Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress

• Date/Time: September 3, 2025, 12:20 pm
• Presenter: Sally Tucker, Ph.D., Senior Vice President Clinical Development
• Format: Panel Discussion
• Location: Paris, France

Opus Genetics Corporate Presentation

• Date/Time: September 3, 2025, 5:00 pm
• Presenter: Sally Tucker, Ph.D., Senior Vice President Clinical Development
• Location: Paris, France
  
  

RD 2025 - International Symposium on Retinal Degeneration

Title: One-year results from a Phase I/II study of OPGx-LCA5 subretinal gene therapy for the treatment of inherited retinal degeneration due to biallelic mutations in the LCA5 gene

• Date: September 15, 2025
• Presenter: Ash Jayagopal, Ph.D., Chief Scientific & Development Officer
• Location: Prague, Czech Republic
  
  

LSX World Congress

Title: The Equation for Maturation: Biotech Requirements to Achieve Scale

• Date/Time: September 17, 2025, 12:40 pm
• Presenter: Ben Yerxa, Ph.D., President
• Format: Panel Discussion
• Location: Boston, MA
  
  

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead gene therapy candidates are OPGx-LCA5, which is in an ongoing Phase 1/2 trial for LCA5-related mutations, and OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and being studied in two Phase 3 programs for presbyopia and reduced low light vision and nighttime visual disturbances. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.

FAQ

When will Opus Genetics (IRD) present its Phase I/II study results for OPGx-LCA5?

Opus Genetics will present the one-year results from its Phase I/II study of OPGx-LCA5 on September 15, 2025 at the International Symposium on Retinal Degeneration in Prague.

What conferences will Opus Genetics (IRD) attend in September 2025?

Opus Genetics will present at four conferences: Ophthalmology Futures Forum in Paris, RD 2025 International Symposium in Prague, and LSX World Congress in Boston.

Who are the key presenters from Opus Genetics (IRD) at the September 2025 conferences?

Key presenters include Dr. Sally Tucker (SVP Clinical Development), Dr. Ash Jayagopal (Chief Scientific & Development Officer), and Dr. Ben Yerxa (President).

What will Opus Genetics (IRD) present at the Ophthalmology Futures Forum?

At the Ophthalmology Futures Forum in Paris on September 3, 2025, Dr. Sally Tucker will participate in a panel discussion titled 'Gene & Cell Therapies for Rare & Common Retinal Diseases: Hype Vs Progress'.